HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption.

AbstractBACKGROUND:
Glioblastoma is one of the intractable cancers and is highly resistant to ionizing radiation. This radioresistance is partly due to the presence of a hypoxic region which is widely found in advanced malignant gliomas. In the present study, we evaluated the effectiveness of the hypoxic cell sensitizer doranidazole (PR-350) using the C6 rat glioblastoma model, focusing on the status of blood brain barrier (BBB).
METHODS:
Reproductive cell death in the rat C6 glioma cell line was determined by means of clonogenic assay. An intracranial C6 glioma model was established for the in vivo experiments. To investigate the status of the BBB in C6 glioma bearing brain, we performed the Evans blue extravasation test. Autoradiography with [(14)C]-doranidazole was performed to examine the distribution of doranidazole in the glioma tumor. T2-weighted MRI was employed to examine the effects of X-irradiation and/or doranidazole on tumor growth.
RESULTS:
Doranidazole significantly enhanced radiation-induced reproductive cell death in vitro under hypoxia, but not under normoxia. The BBB in C6-bearing brain was completely disrupted and [(14)C]-doranidazole specifically penetrated the tumor regions. Combined treatment with X-irradiation and doranidazole significantly inhibited the growth of C6 gliomas.
CONCLUSIONS:
Our results revealed that BBB disruption in glioma enables BBB-impermeable radiosensitizers to penetrate and distribute in the target region. This study is the first to propose that in malignant glioma the administration of hydrophilic hypoxic radiosensitizers could be a potent strategy for improving the clinical outcome of radiotherapy without side effects.
AuthorsHironobu Yasui, Taketoshi Asanuma, Junichi Kino, Tohru Yamamori, Shunsuke Meike, Masaki Nagane, Nobuo Kubota, Mikinori Kuwabara, Osamu Inanami
JournalBMC cancer (BMC Cancer) Vol. 13 Pg. 106 (Mar 08 2013) ISSN: 1471-2407 [Electronic] England
PMID23496909 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Imidazoles
  • Radiation-Sensitizing Agents
  • doranidazole
Topics
  • Animals
  • Blood-Brain Barrier (drug effects)
  • Brain Neoplasms (pathology, radiotherapy)
  • Cell Death (drug effects)
  • Cell Line, Tumor
  • Disease Models, Animal
  • Glioblastoma (pathology, radiotherapy)
  • Imidazoles (pharmacology)
  • Prospective Studies
  • Radiation-Sensitizing Agents (pharmacology)
  • Rats

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: